249 related articles for article (PubMed ID: 7969041)
1. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.
Lee JS; Paull K; Alvarez M; Hose C; Monks A; Grever M; Fojo AT; Bates SE
Mol Pharmacol; 1994 Oct; 46(4):627-38. PubMed ID: 7969041
[TBL] [Abstract][Full Text] [Related]
2. DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux.
Minderman H; Vanhoefer U; Toth K; Yin MB; Minderman MD; Wrzosek C; Slovak ML; Rustum YM
Cytometry; 1996 Sep; 25(1):14-20. PubMed ID: 8875050
[TBL] [Abstract][Full Text] [Related]
3. Liposome composition is important for retention of liposomal rhodamine in P-glycoprotein-overexpressing cancer cells.
Kang DI; Kang HK; Gwak HS; Han HK; Lim SJ
Drug Deliv; 2009 Jul; 16(5):261-7. PubMed ID: 19538007
[TBL] [Abstract][Full Text] [Related]
4. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen.
Alvarez M; Paull K; Monks A; Hose C; Lee JS; Weinstein J; Grever M; Bates S; Fojo T
J Clin Invest; 1995 May; 95(5):2205-14. PubMed ID: 7738186
[TBL] [Abstract][Full Text] [Related]
5. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay.
Lamy T; Drenou B; Grulois I; Fardel O; Jacquelinet C; Goasguen J; Dauriac C; Amiot L; Bernard M; Fauchet R
Leukemia; 1995 Sep; 9(9):1549-55. PubMed ID: 7658724
[TBL] [Abstract][Full Text] [Related]
6. Benzquinamide inhibits P-glycoprotein mediated drug efflux and potentiates anticancer agent cytotoxicity in multidrug resistant cells.
Mazzanti R; Croop JM; Gatmaitan Z; Budding M; Steiglitz K; Arceci R; Arias IM
Oncol Res; 1992; 4(8-9):359-65. PubMed ID: 1362504
[TBL] [Abstract][Full Text] [Related]
7. Effects of hypotonic and hypoionic media on drug pumping by P-glycoprotein expressed in epithelial and nonepithelial cell lines.
Ambasch K; Cabantchik ZI; Slotki IN
J Cell Physiol; 1995 Jul; 164(1):117-22. PubMed ID: 7790383
[TBL] [Abstract][Full Text] [Related]
8. Rhodamine 123: is it an appropriate dye to study P-glycoprotein activity in adriamycin-resistant K562 cells?
Denis-Gay M; Petit JM; Ratinaud MH
Anticancer Res; 1995; 15(1):121-6. PubMed ID: 7733620
[TBL] [Abstract][Full Text] [Related]
9. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells.
Sachs-Barrable K; Thamboo A; Lee SD; Wasan KM
J Pharm Pharm Sci; 2007; 10(3):319-31. PubMed ID: 17727795
[TBL] [Abstract][Full Text] [Related]
10. Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line.
Romiti N; Tramonti G; Chieli E
Toxicol Appl Pharmacol; 2002 Sep; 183(2):83-91. PubMed ID: 12387747
[TBL] [Abstract][Full Text] [Related]
11. Effects of vinblastine, colchicine, and verapamil on rhodamine 123 accumulation in human P-glycoprotein-positive leukemia cells.
Lautier D; Canitrot Y; Salmon JM
Anticancer Res; 1994; 14(6B):2589-95. PubMed ID: 7872686
[TBL] [Abstract][Full Text] [Related]
12. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells.
Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX
Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236
[TBL] [Abstract][Full Text] [Related]
13. Modulation of P-glycoprotein-mediated multidrug resistance by flavonoid derivatives and analogues.
Hadjeri M; Barbier M; Ronot X; Mariotte AM; Boumendjel A; Boutonnat J
J Med Chem; 2003 May; 46(11):2125-31. PubMed ID: 12747785
[TBL] [Abstract][Full Text] [Related]
14. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane.
Regev R; Katzir H; Yeheskely-Hayon D; Eytan GD
FEBS J; 2007 Dec; 274(23):6204-14. PubMed ID: 17986257
[TBL] [Abstract][Full Text] [Related]
15. Relationship of multidrug resistance to rhodamine-123 selectivity between carcinoma and normal epithelial cells: taxol and vinblastine modulate drug efflux.
Brouty-Boyé D; Kolonias D; Wu CJ; Savaraj N; Lampidis TJ
Cancer Res; 1995 Apr; 55(8):1633-8. PubMed ID: 7712466
[TBL] [Abstract][Full Text] [Related]
16. Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics, and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation.
Ibrahim S; Peggins J; Knapton A; Licht T; Aszalos A
Anticancer Res; 2001; 21(2A):847-56. PubMed ID: 11396174
[TBL] [Abstract][Full Text] [Related]
17. Multidrug resistance reversal in mouse lymphoma cells by heterocyclic compounds.
Molnár J; Szabo D; Mándi Y; Mucsi I; Fischer J; Varga A; König S; Motohashi N
Anticancer Res; 1998; 18(4C):3033-8. PubMed ID: 9713505
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometric assessment of the cellular pharmacokinetics of fluorescent drugs.
Dordal MS; Ho AC; Jackson-Stone M; Fu YF; Goolsby CL; Winter JN
Cytometry; 1995 Aug; 20(4):307-14. PubMed ID: 7587718
[TBL] [Abstract][Full Text] [Related]
19. Topological folding and proteolysis profile of P-glycoprotein in membranes of multidrug-resistant cells: implications for the drug-transport mechanism.
Zhang M; Wang G; Shapiro A; Zhang JT
Biochemistry; 1996 Jul; 35(30):9728-36. PubMed ID: 8703944
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin.
Barthomeuf C; Grassi J; Demeule M; Fournier C; Boivin D; Béliveau R
Cancer Chemother Pharmacol; 2005 Aug; 56(2):173-81. PubMed ID: 15824923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
